Feature

InfoBionic.Ai innovating a beat ahead with gold standard remote cardiac care

Closely-held InfoBionic.Ai, a pioneering virtual cardiac telemetry company, is transforming cardiac patient care by equipping healthcare providers with a sophisticated ecosystem of solutions designed to enhance every...

September 17, 2024

Feature

Model Medicines innovates by bringing together data science and biology to develop drugs

Closely-held Model Medicines is spearheading the use of AI to model chemistry and human biology, empowering drug discovery and creating novel, best-in-class therapeutics for diseases with high unmet medical needs at...

September 3, 2024

Feature

Entera Bio’s EB613 Oral PTH(1-34) Tablets Poised to Revolutionize Osteoporosis Care for 200 Million Post-Menopausal Women Globally

Entera Bio (NASDAQ:ENTX) is leveraging a disruptive technology platform called N-Tab to develop first-in-class, once-daily oral tablets of peptides and small therapeutic protein replacement therapies. The company...

August 20, 2024

Feature

Mauna Kea launches groundbreaking food-related IBS detection and treatment program

Mauna Kea Technologies (Euronext Growth:ALMKT), inventor of the world’s first and only real-time in vivo cellular imaging platform, Cellvizio, designed to deliver high-magnification visualization of cellular structures...

August 6, 2024

NEWS

Opthea names Kathy Connell to BOD

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

InfoBionic.Ai innovating a beat ahead with gold standard remote cardiac care

Model Medicines innovates by bringing together data science and biology to develop drugs

Entera Bio’s EB613 Oral PTH(1-34) Tablets Poised to Revolutionize Osteoporosis Care for 200 Million Post-Menopausal Women Globally

Mauna Kea launches groundbreaking food-related IBS detection and treatment program

NEWS

Opthea names Kathy Connell to BOD

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

Eupraxia reports new positive data from RESOLVE trial of EP-104GI in EoE

Lipella’s liposomal delivery platform granted patent by USPTO

FDA grants ODD to Mustang’s MB-108 for malignant glioma

USPTO grants second patent for Eton’s ET-400

Alterity underscores published data on role of iron in neurodegenerative diseases

BioRestorative to unveil key Phase 2 findings on BRTX-100 for cLDD at ORS PSRS International Spine Research Symposium

Just a few of the companies we’ve highlighted along the way

General

More